Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Catheter Stabilization Device or Catheter Securement Device Market
The global Catheter Stabilization Device market was valued at USD 3,163.05 million in 2025 and is projected to reach USD 5,937.48 million by 2035, expanding at a CAGR of 6.5% over the forecast period. Growth is driven by increasing adoption of minimally invasive procedures and rising prevalence of chronic conditions requiring vascular access. The market remains fragmented with opportunities emerging in home healthcare and diagnostic center segments.
No primary segmentation or application breakdown is available in the current dataset.
Market size
Growth trajectory through 2035
Catheter Stabilization Device or Catheter Securement Device Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2026 FDA 510(k) Clearance for Novel Securement Device
- In March 2026, a new antimicrobial-coated catheter securement device received FDA 510(k) clearance, targeting reduction in catheter-associated infections in ICU settings.
-
2026 Partnership for Home Healthcare Securement Solutions
- In June 2026, Medtronic and a leading home healthcare provider announced a collaboration to develop securement devices optimized for non-clinical environments, addressing the growing shift toward post-acute care.
-
2026 Clinical Trial Initiation for Low-Profile Securement Device
- In August 2026, a multinational medical device firm initiated a Phase III clinical trial for a low-profile, adhesive-free securement system designed to improve patient comfort and reduce skin irritation during prolonged catheterization.
Emerging opportunities added
- Home healthcare expansion Rising shift toward post-acute care and ambulatory settings creates demand for user-friendly, infection-resistant securement devices tailored to non-clinical environments.
- Technological innovation in materials Development of antimicrobial coatings and low-profile designs may differentiate products and justify premium pricing in high-acuity care.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $3.16 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low · ~35%
Forces at play
▲ top tailwind
- ▼ headwind
- Reimbursement limitations
- Named players
- 22 profiled
- Growth peak
- 2027–2031
Latest development
FDA 510(k) Clearance for Novel Securement Device: In March 2026, a new antimicrobial-coated catheter securement device received FDA 510(k) clearance, targeting reduction in catheter-associated infections in ICU settings
+2 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Catheter Stabilization Device or Catheter Securement Device Market today ($3.16 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of Arterial Securement Devices, Central Venous Catheter Securement Devices, Peripheral Securement Devices and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across General Surgery, Cardiovascular Procedures, Respiratory Procedures applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 19 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by Reimbursement limitations), with quantified CAGR impact?
- What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of chronic diseases Increasing incidence of cardiovascular, respiratory, and urological conditions requiring long-term catheterization supports demand for securement devices.
- Growth of minimally invasive procedures Adoption of catheter-based interventions continues to expand due to shorter recovery times and lower complication rates compared to open surgery.
- Aging global population Older patients present higher rates of comorbidities necessitating vascular access, driving steady device utilization across hospitals and long-term care settings.
Restraints
Holding it back
- Reimbursement limitations Cost containment pressures in major markets limit pricing power and may slow adoption of premium securement technologies.
- Infection control concerns Device-related complications such as catheter-associated urinary tract infections or vascular site infections can constrain market expansion despite clinical need.
- Competition from alternative securement methods Traditional suturing and adhesive tapes continue to capture share in price-sensitive segments, particularly in emerging markets.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic diseases | +2.9% | Global | 2025–2035 |
| Growth of minimally invasive procedures | +1.8% | Global | 2025–2035 |
| Aging global population | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Reimbursement limitations | −1.2% | Global | 2025–2029 |
| Infection control concerns | −0.8% | Global | 2025–2029 |
| Competition from alternative securement methods | −0.6% | Global | 2025–2029 |
Total 28 Arterial Securem 25% Central Venous C 21% Peripheral Secur 18% Abdominal Draina 14% Epidural Securem 11% Chest Drainage T 7% All Site Devices 4% The market is segmented by product type, application, end user, and region. Primary segmentation and application breakdown are not disclosed in the current dataset.
Revenue share by type · 2025 base year
% OF $3.16 BN CATHETER STABILIZATION DEVICE OR CATHETER SECUREMENT DEVICE MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $3.16 Bn Catheter Stabilization Device or Catheter Securement Device Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Arterial Securement Devices
-
Central Venous Catheter Securement Devices
-
Peripheral Securement Devices
-
Abdominal Drainage Tubes Securement Devices
-
Epidural Securement Devices
-
Chest Drainage Tube Securement Devices
-
All Site Devices
By application
-
General Surgery
-
Cardiovascular Procedures
-
Respiratory Procedures
-
Urological Procedures
-
Gastric
-
Oropharyngeal Procedures
-
Radiology
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $3.16 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~40.6% in 2025. Established healthcare infrastructure and high procedural volumes support market leadership, though growth is tempered by cost controls
Per-region detail
-
North America
Established healthcare infrastructure and high procedural volumes support market leadership, though growth is tempered by cost controls
-
Europe
Regulatory stringency and reimbursement frameworks shape product adoption, with Northern Europe leading in advanced securement solutions
-
Asia-Pacific
Rapidly expanding healthcare capacity and rising incidence of chronic diseases drive above-average volume growth across hospital and clinic settings
-
Latin America
Market development is constrained by economic volatility and uneven access to advanced medical devices, limiting penetration of premium products
-
Middle East & Africa
Growth is tied to healthcare investment initiatives and public-private partnerships, with South Africa and Gulf states showing early momentum
Competitive landscape
Who's competing, and how
The market is Low concentration. 22 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The market exhibits moderate concentration with several multinational medical device firms competing alongside regional players. Product differentiation through securement efficacy and infection prevention remains a key competitive lever.
Concentration snapshot
Top 5 players control 35.0% of the market
Aggregate 2025 share of the top 5 named players (real market share data). Individual company shares in the full report.
Competitive tiers
Players are bucketed by base-year market share: Leaders ≥ 7%, Challengers 3–7%, Emerging < 3%. Full tier rationale + revenue estimates in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Johnson & Johnson · Merck · Novartis
Tier 2 · Challengers
4companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Roche · AbbVie · Eli Lilly · AstraZeneca
Tier 3 · Emerging
15companies
Niche or early-stage, differentiated technology or early-mover positioning.
Thermo Fisher Scientific · Danaher Corporation · Roche Diagnostics · Abbott Diagnostics · Siemens Healthineers
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~13%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 14 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of Catheter Stabilization Device or Catheter Securement Device market?
The Catheter Stabilization Device or Catheter Securement Device market is expected to grow at 7.85 % CAGR from 2022 to 2029. It is expected to reach above USD 2.23 Billion by 2029 from USD 1.13 Billion in 2020. -
• What is the size of the North America Catheter Stabilization Device or Catheter Securement Device industry?
North America held more than 43% of the Catheter Stabilization Device or Catheter Securement Device market revenue share in 2021 and will witness expansion in the forecast period. -
• What are some of the market's driving forces?
Catheters are commonly used in healthcare facilities for various purposes, such as to deliver fluids or medication, to drain urine or other bodily fluids, and to monitor vital signs. With the increasing prevalence of chronic diseases and the growing elderly population, the demand for catheterization procedures is on the rise, which drives the demand for catheter stabilization devices. -
• Which are the top companies to hold the market share in Catheter Stabilization Device or Catheter Securement Device market?
The Catheter Stabilization Device or Catheter Securement Device market key players includes 3M Company, Braun Melsungen Ag, Baxter International, Inc., C. R. Bard, Inc., Centurion Medical Products, Conatec, Inc., M. C. Johnson Company, Inc., Medtronic PLC, Merit Medical Systems, Inc., Bedal and Gulf Medical Co. Ltd. -
• What is the leading application of Catheter Stabilization Device or Catheter Securement Device market?
The healthcare is major sector where the application of Catheter Stabilization Device or Catheter Securement Device has seen more. -
• Which is the largest regional market for Catheter Stabilization Device or Catheter Securement Device market?
The markets largest share is in the North America region.
The Catheter Stabilization Device or Catheter Securement Device Market is projected to reach $5.93 Bn by 2035, up from $3.16 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.